Robert Griffin

Federal Grant PI High Impact

Professor

UAMS

Last publication 2024 Last refreshed 2026-05-22

faculty

Radiation Oncology, College of Medicine

rjgriffin@uams.edu

71 h-index 499 pubs 25,813 cited

Research Areas

Links

ORCID Google Scholar Lab Website Research Group UAMS TRI Profile

OverviewAI-generated summary

Robert Griffin is a Professor in the Department of Radiation Oncology at the University of Arkansas for Medical Sciences. His research focuses on understanding and improving cancer treatments, particularly in the context of non-small cell lung cancer and immunotherapy. Griffin has investigated targeted inhibitors for specific cancer mutations, such as mobocertinib for EGFR exon 20 insertion mutants.

His work also explores novel approaches to enhance anti-tumor immunity and the efficacy of radiation therapy. This includes research into the role of HIF-1α inhibition in improving anti-tumor immunity and promoting the effectiveness of stereotactic ablative radiotherapy (SABR). Griffin has also contributed to the development of systemic intravenous STING agonists for antitumor immunotherapy, utilizing carbocyclic pyrimidine cyclic dinucleotides.

Beyond oncology, Griffin's research interests extend to the role of exosomes in cellular processes and their potential therapeutic applications, as seen in studies on exosome traceability and MSC exosome-mediated cardioprotection. He has also explored the role of specific microRNAs, such as miR-2392, in viral infections like SARS-CoV-2. Griffin's scholarship metrics include an h-index of 34, with 285 total publications and 4,665 total citations. He has served as PI on a $270,624 NIH/National Cancer Institute grant focused on Cancer and Developing Entrepreneurial Technologies (CADET).

Metrics

h-index: 71
Publications: 499
Citations: 25,813

Selected Publications

Abstract 4785: Thermal regulation of dysbiotic tumor vasculature (2026)

DOI OpenAlex
Abstract 7625: Development of a blood-based tumor hypoxia detection assay (2026)

DOI OpenAlex
Modified tumor uptake and biodistribution of nanoparticles coated with small extracellular vesicle membranes derived from distinct tumor cell lines (2026)

DOI OpenAlex
Pancreatic cancer extracellular vesicles stimulate Schwann cell activation and perineural invasion in vitro via IL-8/CCL2 (2025)

4 citations DOI OpenAlex
Abstract B026: Pancreatic tumor extracellular vesicles induce perineural invasion in vitro via IL- 8/CCL2 (2024)

1 citation DOI OpenAlex
The Radiosurgery Society Working Groups on GRID, LATTICE, Microbeam, and FLASH Radiotherapies: Advancements Symposium and Subsequent Progress Made (2024)

4 citations DOI OpenAlex
Interrogating the Role of Endocytosis Pathway and Organelle Trafficking for Doxorubicin-Based Combination Ionic Nanomedicines (2024)

6 citations DOI OpenAlex
Innovations in Physics, Biology and Clinical Translation of Spatially Fractionated and FLASH Radiotherapy (2024)

1 citation DOI OpenAlex
Bystander Effects in Spatially Fractionated Radiation Therapy: From Molecule To Organism To Clinical Implications (2024)

9 citations DOI OpenAlex
Doxorubicin-Based Ionic Nanomedicines for Combined Chemo-Phototherapy of Cancer (2024)

8 citations DOI OpenAlex
Overview and Recommendations for Prospective Multi-institutional Spatially Fractionated Radiation Therapy Clinical Trials (2023)

39 citations DOI OpenAlex
Cationic Porphyrin-Based Ionic Nanomedicines for Improved Photodynamic Therapy (2023)

7 citations DOI OpenAlex
Morphological Effects and In Vitro Biological Mechanisms of Radiation-Induced Cell Killing by Gold Nanomaterials (2023)

2 citations DOI OpenAlex
Exosomal MicroRNA and Protein Profiles of Hepatitis B Virus-Related Hepatocellular Carcinoma Cells (2023)

10 citations DOI OpenAlex
Practice Patterns of Spatially Fractionated Radiation Therapy: A Clinical Practice Survey (2023)

33 citations DOI OpenAlex

View all publications on OpenAlex →

Federal Grants 1 $270,624 total

NIH/National Cancer Institute Contact PI Sep 2025 - Aug 2030

Cancer and Developing Entrepreneurial Technologies (CADET)

National Cancer Institute $270,624 R25

Grants & Funding

Detection of hypoxia markers in tumor exosomes using Raman spectroscopy University of Arkansas at Fayetteville Principal Investigator
Functional optical biomarkers of response to therapy in head and neck squamous cell carcinoma- Resubmission Arkansas Economic Development Commission - Pass Through: National Science Foundation Principal Investigator
Improvement of cellular immunotherapy during dysbiosis NIH/Nat. Cancer Institute Principal Investigator
RII Track-1: Arkansas ASSET Initiative III - Continuation Y5 - Continuation National Science Foundation - Pass Through: Arkansas Economic Development Commission Principal Investigator
Physiological Factors in Hyperthermia NIH Principal Investigator
Determination of functional and molecular biomarkers of treatment resistance with multimodal optical spectroscopy- Resubmission NIH/Nat. Cancer Institute - Pass Through: University of Arkansas at Fayetteville Co-Investigator
Functional optical biomarkers of response to therapy in head and neck squamous cell carcinoma- Resubmission Arkansas Economic Development Commission - Pass Through: National Science Foundation Principal Investigator
Functional optical biomarkers of response to therapy in head and neck squamous cell carcinoma- Resubmission Arkansas Economic Development Commission - Pass Through: National Science Foundation Principal Investigator